Health
Phico Therapeutics awarded up to $18.2 million USD (c.£13.2 million GBP) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials – News-Medical.net
Phico Therapeutics has been awarded a grant of up to $18.2 million USD to tackle the global rising threat of drug-resistant bacteria.
Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to $18.2 million USD (circa. £13.2 million GBP) from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
Phico Therapeutics…
-
Noosa News13 hours agoThe Pedro Pascal-Led Fantastic Four Face Julia Garner’s Silver Surfer in the New Full ‘First Steps’ Trailer
-
General13 hours agoFrom Humpty Doo to the bush, these voters’ views reflect the challenge for federal politicians
-
General11 hours agoNew Zealand wants more ‘automated decision-making’ in its welfare system. Could that lead to Robodebt 2.0?
-
Noosa News16 hours agoQueensland set for ‘comfortable’ weather over Easter long weekend